In the collaboration ImQuest will provide complete preclinical and clinical drug development support for therapeutic small molecules discovered by Samjin Pharmaceutical.
“This relationship merges the significant individual strengths of both companies,” commented Jerry Cartright, ImQuest Pharmaceuticals’ CEO. “Samjin’s medicinal chemistry team will provide new entities that will be developed using ImQuest’s preclinical and clinical development expertise.”
ImQuest is a US based developer of novel therapeutic agents for the treatment of infectious disease, cancer and inflammatory disease, with lead candidates for HIV therapy and microbicide treatment in late preclinical development. Samjin is one of the leading pharmaceutical companies in Korea with projected sales for 2005 estimated at $120 million.